Objectives: To longitudinally evaluate the association of post-ICU muscle weakness and associated trajectories of weakness over time with 5-year survival. Design: Longitudinal prospective cohort study over 5 years of follow-up. Setting: Thirteen ICUs in four hospitals in Baltimore, MD. Patients: One hundred fifty-six acute respiratory distress syndrome survivors. Interventions: None. Measurements and Main Results: Strength was evaluated with standardized manual muscle testing using the Medical Research Council sum score (range, 0-60; higher is better), with post-ICU weakness defined as sum score less than 48. Muscle strength was assessed at hospital discharge and at 3, 6, 12, 24, 36, and 48 months after acute respiratory distress syndrome. At discharge, 38% of patients had muscle weakness. Every one point increase in sum score at discharge was associated with improved survival (hazard ratio [95% CI], 0.96 [0.94-0.98]), with similar findings longitudinally (0.95 [0.93-0.98]). Having weakness at discharge was associated with worse 5-year survival (1.75 [1.01-3.03]), but the association was attenuated (1.54 [0.82-2.89]) when evaluated longitudinally over follow-up. Persisting and resolving trajectories of muscle weakness, occurring in 50% of patients during follow-up, were associated with worse survival (3.01 [1.12-8.04]; and 3.14 [1.40-7.03], respectively) compared to a trajectory of maintaining no muscle weakness. Conclusions: At hospital discharge, greater than one third of acute respiratory distress syndrome survivors had muscle weakness. Greater strength at discharge and throughout follow-up was associated with improved 5-year survival. In patients with post-ICU weakness, both persisting and resolving trajectories were commonly experienced and associated with worse survival during follow-up. (Crit Care Med 2017; 45:446-453) 
D espite improving in-patient mortality for patients with acute respiratory distress syndrome (ARDS) and other critical illnesses (1) (2) (3) , survivors face increased mortality after hospital discharge (4) (5) (6) (7) (8) . Survivors also face muscle weakness and related physical impairments that persist for months and years after ARDS (9) (10) (11) , with recent studies demonstrating that objective in-patient measures of muscle weakness were associated with hospital mortality (12, 13) and worse survival up to 1 year later (14, 15) .
These findings justify the need to better understand longer term patient outcomes beyond the initial months of recovery, including patient survival and associations of muscle weakness with long-term survival. Our objective, therefore, was to longitudinally evaluate the association of post-ICU muscle weakness with long-term survival until 5 years after ARDS, specifically evaluating muscle strength measured prior to hospital discharge and longitudinally thereafter. Additionally, we evaluate the association of trajectories in patients' recovery from muscle weakness in the years after ARDS and their subsequent survival.
METHODS

Study Design and Patients
In this cohort study, conducted in 13 medical, surgical, and trauma ICUs at four teaching hospitals in Baltimore, MD, we prospectively screened and enrolled consecutive mechanically ventilated patients meeting the American-European Consensus Conference criteria for acute lung injury (ALI) (16) that were in effect during the time of enrollment. Throughout this report, we use the term "ARDS," rather than ALI, to be consistent with the more recent Berlin definition (17) . Relevant exclusion criteria included: 1) high short-term mortality unrelated to ARDS (life expectancy < 6 mo due to preexisting illness or a physician order limiting the use of life support therapies at onset of ARDS); 2) important barrier to exposure or outcome assessment (preexisting cognitive impairment, communication/language barrier, or homelessness); and 3) substantial exposure to critical illness/critical care services prior to enrollment (mechanically ventilated for > 5 d before ARDS onset or transfer from another hospital with preexisting ARDS of > 24 hr duration). Institutional review board approval was obtained from all participating sites, and written informed consent was obtained from all participants.
Primary Outcome: 5-Year Survival Consenting patients were prospectively evaluated at 3, 6, 12, 24, 36, 48 , and 60 months after ARDS onset. Vital status along with date and cause of death was ascertained from family members, with death date verified via a commercial version of the Social Security Death Master File (18) . Patients for whom vital status could not be determined were censored at their last day known to be alive.
Primary Exposure: Muscle Strength
As commonly done in prior critical care research (12, 15, (19) (20) (21) , patients' muscle strength was evaluated via standardized physical examination using manual muscle testing and the Medical Research Council (MRC) sum score (range, 0-60; higher score is better). All strength assessors underwent initial training and ongoing quality assurance review by a referencerater (N. D. C.) with high interrater reliability (22) . Patients' strength was evaluated prior to hospital discharge and at each follow-up assessment. Muscle strength was evaluated both as a continuous (MRC sum score) and binary (MRC sum score < 48) exposure variable. The binary evaluation of muscle strength, referred to hereafter as "post-ICU-weakness," was defined as per prior research (10, 13, 15, 20) .
Potential Confounders
Based on a prior publication (23), a subset of risk factors for mortality after ARDS was considered for inclusion in this analysis as potential confounders of the exposure-outcome relationship. These variables included patient factors: age, sex, body mass index, and baseline comorbidity (Charlson comorbidity index [24] > 1); and the following ICU factors: Acute Physiology and Chronic Health Evaluation II (25) score within the first 24 hours of ICU admission, ARDS risk factor (sepsis vs nonsepsis), type of ICU (medical ICU vs other), source of admission (e.g., emergency department), mean daily Sequential Organ Failure Assessment (SOFA) (26) score in the ICU, daily sedation (Richmond Assessment of Sedation Scale) (27) and delirium (Confusion Assessment Method for the ICU) (28) status, cumulative dose of systemic corticosteroids and neuromuscular blocking medications, and the number of days with these medications, cumulative fluid balance, mean daily positive end-expiratory pressure, mean daily ratio of Pao 2 /Fio 2 , mean daily static lung compliance, mean tidal volume (per kilogram of predicted body weight) (29) , mean daily respiratory rate (breaths/min), total days of mechanical ventilation, and ICU length of stay (LOS). Missing data among potential confounders were rare (< 1%) except for sedation and delirium. Multiple imputation was used for the missing sedation and delirium assessments as described elsewhere (30) .
Statistical Methods
Descriptive statistics included median and interquartile range (IQR) for continuous variables and percentages for categorical variables, with comparisons conducted using Wilcoxon rank-sum and Fisher exact tests, respectively. Locally weighted regression (LOESS) was used to assess for linearity of association between continuous variable and survival, and if not linear, then they were categorized, as appropriate, based on the LOESS (e.g., Charlson comorbidity index, see supplemental data, Supplementary Digital Content 1, http:// links.lww.com/CCM/C277). A Kaplan-Meier curve was used to describe the survival from hospital discharge until 5 years after ARDS onset, and a lasagna plot (31) was created to visualize muscle weakness trajectories over 5-year followup ( Supplementary Fig. 1 Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/C277). Variance inflation factors were evaluated to confirm the absence of multicollinearity of these potential confounders. Both continuous and binary measures of muscle strength at hospital discharge were then evaluated in separate multivariable Cox regression models adjusting for these three potential confounders. Additionally, both measures of muscle strength were evaluated as time-varying exposures in separate multivariable Cox regression models adjusting for the same potential confounders. For each multivariable model, Martingale residual plots were assessed to confirm that there were no departures from linearity for continuous exposure and confounder variables. In addition, Schoenfeld residual plots were assessed to evaluate the proportional hazards assumption which demonstrated some evidence of nonproportional hazards over time for MRC sum score and post-ICU weakness indicator; however, since the estimated hazard ratios (HRs) within each year of follow-up were qualitatively similar, a single HR is reported for each exposure variable.
In addition to evaluating muscle strength at hospital discharge and each follow-up assessment, changes in post-ICU muscle weakness over time (i.e., trajectories of muscle weakness) were evaluated longitudinally, in a time-varying manner, using the same multivariable Cox regression model described above. For this analysis, patients needed to survive for at least two strength assessments to evaluate change over time (i.e., trajectory). This time-varying exposure of change in weakness from one time point to the next was categorized as "no weakness" (i.e., consecutive assessments of no weakness and no weakness), "persisting weakness" (i.e., from weakness to weakness), "resolving weakness" (i.e., from weakness to no weakness), and "new weakness" (i.e., from no weakness at or after hospital discharge to subsequent weakness).
RESULTS
There were 156 consenting and eligible patients for evaluation in this analysis (Fig. 1) . Of these 156 patients surviving until hospital discharge, 53 (34%) died after hospital discharge during 5-year follow-up (Fig. 2) , with the following categories for causes of death: infection 16 (30%), cardiovascular 11 (21%), cancer six (11%), gastrointestinal four (8%), respiratory four (8%), renal three (6%), other causes three (6%), and unknown cause six (11%) (for trends over time for top two causes of death; see Supplemental Table 2 , Supplemental Digital Content 1, http://links.lww.com/CCM/C277). Those who died were significantly older with greater comorbidity, organ failure and days of delirium in the ICU, and hospital LOS ( Table 1) . At hospital discharge, 38% of patients had post-ICU muscle weakness, and the median (IQR) MRC sum score was significantly lower for those who died during 5-year follow-up versus survivors (44 [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] vs 51 [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] ; p < 0.001), with 55% versus 30% (p = 0.003) having post-ICU muscle weakness (Table 1) .
After adjusting for age, Charlson comorbidity index, and mean daily SOFA score, increased muscle strength at hospital discharge was associated with long-term survival ( Table 2 ). There were 588 consecutive assessments from 140 patients in this study, including 38 assessments (7%) from 22 patients (16%) demonstrating persisting weakness and 70 assessments (12%) from 63 patients (45%) demonstrating resolving weakness ( Table 3 , see Supplementary Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/C277). Compared with a trajectory of maintaining no weakness, both persistent and resolving weakness trajectories were associated with significantly worse survival (3.01; 1.12-8.04; p = 0.028 and 3.14; 1.40-7.03; p = 0.005, respectively) ( Table 3) , whereas a trajectory of "new weakness" (i.e., going from "no weakness" at or after hospital discharge to subsequent "weakness") was not associated with subsequent survival (0.99; 0.22-4.43; p = 0.985).
DISCUSSION
This 5 year, prospective multisite longitudinal follow-up study of 156 ARDS survivors found that 38% had muscle weakness at hospital discharge, and that greater muscle strength at both hospital discharge and longitudinally during follow-up was independently associated with improved survival. Trajectories of persistent and resolving weakness were experienced by 50% of patients and both trajectories were associated with a more than three times greater hazard of subsequent death.
Given improving in-patient survival for patients with ARDS and other critical illnesses (1-3), but ongoing mortality after hospital discharge (4-8), understanding potential risk factors or markers for decreased long-term survival can help identify potential interventions to evaluate in future studies. (15) . We build on these prior studies by evaluating the association of post-ICU weakness with long-term survival over 5 years, where roughly half of the deaths occurred during years 2-5. In our study, we found that at hospital discharge, increased muscle strength is associated with improved survival and having muscle weakness (i.e., a sum score < 48) is associated with worse survival over 5-year follow-up.
Additionally, our study is novel in that muscle strength was assessed not only in-hospital but also longitudinally over 5-year follow-up. Postdischarge muscle weakness is an important aspect of survivorship since it is associated with impaired respiratory muscle strength, physical functioning, and quality of life (10) . In our longitudinal analyses, greater muscle strength was associated with improved survival; however, the association with binary modeling of muscle weakness (i.e., sum score < 48) was attenuated, becoming nonsignificant, perhaps due to decreased prevalence of muscle weakness and mortality in the cohort over the duration of follow-up. Lastly, longitudinal evaluation of muscle strength allowed for a novel exploration of the association of trajectories of muscle weakness over time with subsequent survival, with our study demonstrating that both persistent weakness and recovering from weakness, which occurred in 50% of patients during follow-up, were similarly associated with worse survival compared with trajectories of no weakness.
Across the multivariable regression analyses in our study, age and baseline comorbidity remained significantly associated with posthospital survival, whereas acute severity of illness in the ICU (e.g., daily SOFA score) was not; a finding that is consistent with previous studies (33, 34) . Even after adjusting for these variables, post-ICU muscle weakness was associated with worse 5-year survival. Future studies should aim to elucidate the mechanisms that link muscle weakness with mortality. For example, muscle weakness in survivors may be a marker for new-onset frailty or preexisting frailty worsened by Corticosteroids doses converted to prednisone-equivalents using standard conversions (32) .
critical illness (35, 36) . The pathogenesis of frailty is hypothesized to involve multisystem dysfunction, including the musculoskeletal system, and be related to chronic inflammation, rendering patients vulnerable to deleterious health outcomes and setting them to a path of progressive decline (37, 38) and decreased survival (39) . Our analyses of post-ICU trajectories of muscle weakness yielded clues that there are likely complex associations of weakness with mortality. In our study, the trajectory of new weakness was not associated with worse survival, signaling that it may represent a period similar to that of a "prefrail" state, a state in which patients are still resistant to physiologic challenges (38) . However, once weak, the patient becomes vulnerable resulting in adverse outcomes, including death. This vulnerability may continue for some time in those with a trajectory of recovery. The risk of adverse outcomes may be higher Proportions will not add up to 100% since a patient can be in more than one category. For this analysis, patients must have at least two strength assessments for which 140 (90%) of 156 patients were eligible. in ICU survivors, even in the recovery process, since they often experience profound and persistent muscle wasting and weakness in the ICU, along other complications of bed rest (10, 40, 41) . These ideas may explain our finding that even a trajectory of resolving weakness was associated with worse survival. Understanding the mechanism(s) linking muscle weakness and mortality will help refine potential interventions to improve long-term survival, but also clarify if a multifaceted approach is necessary to mitigate the posthospital mortality in ICU survivors. For now, with currently available evidence, prevention of muscle weakness via starting rehabilitation interventions shortly after start of mechanical ventilation may be an important consideration for improving long-term outcomes (42) (43) (44) . For example, one study demonstrated that early ICU rehabilitation was associated with decreased 1-year rehospitalization and mortality (45) .
This study has several strengths, including being a multisite, prospective study with long-term, longitudinal follow-up until 5 years after ARDS. This study also has potential limitations. First, this study could not prospectively measure pre-ICU muscle strength as these ARDS patients were typically admitted emergently; hence, just as in routine clinical practice, we are unable to determine if the post-ICU weakness is incident or prevalent. Nonetheless, these findings have clinical value in indicating that post-ICU weakness, irrespective of baseline status, has prognostic significance for long-term survival, even after accounting for patient age, comorbidity, and severity of organ failure in the ICU. Second, one third of patients could not be assessed for muscle strength prior to discharge, excluding them from analyses. However, these excluded patients were generally similar to the cohort of patients retained in this study, except for older age and greater dependency in ADLs at hospital discharge (Supplementary Table 3 , Supplemental Digital Content 1, http://links.lww.com/CCM/C277). Hence, the observed associations with survival may be conservative. Furthermore, only 3% of patients were unable to complete strength assessment at least once during the course of followup, helping minimize bias in our longitudinal assessments. Third, this study could not adjust for other factors (e.g., pre-ICU frailty, chronic inflammation, any interventions such as physical rehabilitation) (46) and potential time-varying confounders (e.g., rehospitalizations) that may have affected the association of muscle weakness with survival. Future studies of long-term survival should account for these issues to potentially refine these associations. Fourth, as an observational study, causality cannot be proven; hence, more research is needed to understand if post-ICU weakness is directly associated with mortality or if post-ICU weakness is a marker for another mechanism more directly responsible for mortality. Lastly, the results of this study may not be generalizable to other ICU populations since only ARDS patients, enrolled from four hospitals in a single city, were studied.
In conclusion, this multisite, prospective longitudinal study found that over one third of ARDS survivors had muscle weakness at hospital discharge. Increased strength at hospital discharge and longitudinally over follow-up was consistently, independently, and significantly associated with improved 5-year survival. Once weak, both resolving and persistent trajectories of weakness were associated with worse subsequent survival, with most patients experiencing these two trajectories during follow-up. Given a growing number of survivors of critical illness, future research should include larger-sized, multicenter studies to confirm these findings. Furthermore, given these findings and complementary results of prior studies evaluating shorter term survival outcomes, future research should evaluate potential mechanisms underlying the association between muscle weakness and survival, and whether early interventions can reduce post-ICU weakness and improve both physical function and survival.
